Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Starpharma Holdings Limited

ABN

20 078 532 180

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- (1) Ordinary Shares
- (2) Rights to Ordinary Shares
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- (1) 1,428,571 Ordinary Shares
- (2) 750,000 Rights to Ordinary Shares
- 3 Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)
- (1) Ordinary fully paid shares
- (2) Rights with a vesting date of 31 Dec 2010 (there may be early vesting if certain events occur). Within 10 Business Days after vesting, one ordinary fully paid share will be issued for each vested Right. Shares issued upon vesting of the Rights will be escrowed until 1 March 2013 provided that the shares may be released early if certain events occur. (As set out in the Explanatory Memorandum that accompanied the Notice of Extraordinary General Meeting mailed to shareholders on 22 February 2010.)

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

(1) Yes

(2) The Rights do not rank equally with an existing class of quoted securities but the ordinary fully paid shares to be issued following vesting of the Rights will rank equally from the date on which they are issued.

5 Issue price or consideration

No consideration.

(As set out in the Explanatory Memorandum that accompanied the Notice of Extraordinary General Meeting mailed to shareholders on 22 February 2010.)

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Grant of Shares and Rights to CEO Dr Jacinth Fairley as part of a long term incentive package following shareholder approval at the General Meeting held 25 March 2010.

7 Dates of entering *securities into uncertificated holdings or despatch of certificates 31 March 2010

8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
238,802,208	Ordinary shares

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the securities in clause 2 if applicable)	12,857,119	Options expiring at various dates ex various prices (SPLAM)
		750,000	Rights issued to Dr Jacinth Fairley as set out in the Explanatory Memorandum that accompanied the Notice of Extraordinary General Meeting mailed to shareholders on 22 February 2010.
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		
Part	2 - Bonus issue or pro	o rata issue	
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	⁺ Class of ⁺ securities to which the offer relates		
15	⁺ Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.		

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of	
20	Names of any underwriters	
21	Amount of any underwriting fee or	
	commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee	
	payable to brokers who lodge acceptances or renunciations on	
	behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance	
	form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and	
	the terms entitle option holders to participate on exercise, the date on	
	which notices will be sent to option holders	
28	Date rights trading will begin (if	
20	applicable)	
29	Date rights trading will end (if applicable)	
30	How do +security holders sell their	
	entitlements in full through a broker?	
31	How do +security holders sell part	
	of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

			1 (0) (255 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
32	of the	do *security holders dispose ir entitlements (except by sale th a broker)?	
33	+Desp	atch date	
Part	t 3 - (Quotation of secur	ities
You nee	ed only c	omplete this section if you are app	ying for quotation of securities
34	Type of tick of	of securities one)	
(a)		Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)			
Additional securities forming a new class of securities			
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36			y securities, a distribution schedule of the additional ber of holders in the categories
37		A copy of any trust deed for the	ne additional +securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of securities for which +quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of		
	another security, clearly identify that other security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (including the securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.

⁺ See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 31 March 2010

Print name: B P Rogers

== == == ==

(Director/Company Secretary)

⁺ See chapter 19 for defined terms.